DRUG TRIALS AND THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

That this House believes that Professor Duff's report on the TGN 1214 drugs trials proves the failures of the regulatory body the Medicines and Healthcare products Regulatory Agency (MHRA), which is funded by the pharmaceutical industry; welcomes the exposure that the MHRA's initial report was a whitewash in claiming that there were `no errors in the administration of the drugs to trial participants'; recalls the Health Select Committee's judgement that `the MHRA's organisation, process and techniques are focused on bringing drugs to market fast' and that the MHRA `has been too close to the industry'; and calls for the Committee's recommendation for fundamental review of the MHRA because of its many failings to be implemented.